Nonoperating Income (Expense) of RELMADA THERAPEUTICS, INC. from 30 Sep 2013 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
RELMADA THERAPEUTICS, INC. quarterly and annual Nonoperating Income (Expense) in USD history and change rate from 30 Sep 2013 to 30 Sep 2025.
  • RELMADA THERAPEUTICS, INC. Nonoperating Income (Expense) for the quarter ending 30 Sep 2025 was $235,850, a 82% decline year-over-year.
  • RELMADA THERAPEUTICS, INC. Nonoperating Income (Expense) for the twelve months ending 30 Sep 2025 was $1,668,102, a 68% decline year-over-year.
  • RELMADA THERAPEUTICS, INC. annual Nonoperating Income (Expense) for 2024 was $3,911,682, a 20% decline from 2023.
  • RELMADA THERAPEUTICS, INC. annual Nonoperating Income (Expense) for 2023 was $4,910,547, a 17% increase from 2022.
  • RELMADA THERAPEUTICS, INC. annual Nonoperating Income (Expense) for 2022 was $4,205,253.
Source SEC data
View on sec.gov
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)

RELMADA THERAPEUTICS, INC. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,668,102 $235,850 -$1,047,018 -82% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $2,715,120 $354,864 -$695,798 -66% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $3,410,918 $658,970 -$500,764 -43% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $3,911,682 $418,418 -$1,245,744 -75% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $5,157,426 $1,282,868 +$592,288 +86% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $4,565,138 $1,050,662 +$326,890 +45% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $4,238,248 $1,159,734 -$672,299 -37% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $4,910,547 $1,664,162 +$906,107 +120% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $4,004,440 $690,580 +$1,372,126 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $2,632,314 $723,772 -$4,853,332 -87% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $7,485,646 $1,832,033 +$3,280,393 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $4,205,253 $758,055 +$953,774 01 Oct 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
Q3 2022 $3,251,479 $681,546 -$728,990 -1537% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $3,980,469 $5,577,104 +$5,667,168 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $1,686,699 $1,448,360 -$1,638,382 -862% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2022 2022 Q1
Q4 2021 $48,317 $195,719 -$357,040 -221% 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 $308,723 $47,444 -$233,631 -83% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $542,354 $90,064 -$1,728,825 -105% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $2,271,179 $190,022 +$888,900 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $1,382,279 $161,321 +$124,174 +334% 01 Oct 2020 31 Dec 2020 10-K 25 Mar 2022 2021 FY
Q3 2020 $1,258,105 $281,075 +$243,159 +641% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $1,014,946 $1,638,761 +$1,625,651 +12400% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $610,705 $698,878 -$714,817 -4485% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021 2021 Q1
Q4 2019 $104,112 $37,147 +$3,687,473 01 Oct 2019 31 Dec 2019 10-K 24 Mar 2021 2020 FY
Q3 2019 $3,583,361 $37,916 +$1,006,779 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $4,590,140 $13,110 +$603,749 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q2
Q1 2019 $5,193,889 $15,939 +$667,912 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020 2020 Q1
Q4 2018 $5,861,801 $3,650,326 -$3,679,561 -12586% 01 Oct 2018 31 Dec 2018 10-Q 13 Feb 2019 2019 Q2
Q3 2018 $2,182,240 $968,863 -$138,863 -17% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019 2020 Q1
Q2 2018 $2,043,377 $590,639 01 Apr 2018 30 Jun 2018 10-KT 26 Mar 2020 2019 FY
Q1 2018 $651,973 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019 2019 Q3
Q4 2017 $29,235 01 Oct 2017 31 Dec 2017 10-Q 13 Feb 2019 2019 Q2
Q3 2017 $830,000 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2019 Q1
Q1 2015 $2,104,868 -$5,100,858 -71% 01 Jan 2015 31 Mar 2015 10-Q 15 May 2015 2015 Q3
Q4 2014 $9,840,259 +$9,951,891 01 Oct 2014 31 Dec 2014 10-Q 13 Feb 2015 2015 Q2
Q3 2014 $26,115,871 -$25,032,490 -2311% 01 Jul 2014 30 Sep 2014 10-Q 07 Nov 2014 2015 Q1
Q1 2014 $7,205,726 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015 2015 Q3
Q4 2013 $111,632 01 Oct 2013 31 Dec 2013 10-Q 13 Feb 2015 2015 Q2
Q3 2013 $1,083,381 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014 2015 Q1

RELMADA THERAPEUTICS, INC. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $3,911,682 -$998,865 -20% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $4,910,547 +$705,294 +17% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $4,205,253 +$4,253,570 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
2021 $48,317 -$1,430,596 -103% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 $1,382,279 +$1,278,167 +1228% 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2022 2021 FY
2019 $104,112 +$2,147,489 01 Jan 2019 31 Dec 2019 10-K 24 Mar 2021 2020 FY
2018 $2,043,377 -$2,975,689 -319% 01 Jul 2017 30 Jun 2018 10-KT 26 Mar 2020 2019 FY
2017 $932,312 01 Jul 2016 30 Jun 2017 10-K 28 Sep 2018 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.